We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$123M
Cap. Flow %
-3.14%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Technology 0.53%
4 Real Estate 0.1%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
76
PepGen
PEPG
$118M
$2.94M 0.07%
+200,000
New +$2.36M
ADAG
77
Adagene
ADAG
$246M
$2.86M 0.07%
1,020,000
+20,000
+2% +$62.3K
GRTS
78
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.65M 0.07%
+1,030,952
New +$2.52M
FATE icon
79
Fate Therapeutics
FATE
$275M
$2.64M 0.07%
+360,311
New +$2.23M
VOR icon
80
Vor Biopharma
VOR
$1.06B
$2.37M 0.06%
50,000
-67,371
-57% -$2.96M
AMZN icon
81
Amazon
AMZN
$2.44T
$2.16M 0.06%
12,000
– –
JANX icon
82
Janux Therapeutics
JANX
$912M
$1.88M 0.05%
+50,000
New +$1.09M
NVDA icon
83
NVIDIA
NVDA
$4.6T
$1.72M 0.04%
+19,000
New +$1.38M
AAPL icon
84
Apple
AAPL
$4.97T
$1.71M 0.04%
+10,000
New +$1.82M
DT icon
85
Dynatrace
DT
$12.7B
$1.67M 0.04%
+36,000
New +$1.87M
ADBE icon
86
Adobe
ADBE
$105B
$1.56M 0.04%
+3,100
New +$1.78M
EDU icon
87
New Oriental
EDU
$9.32B
$1.3M 0.03%
+15,000
New +$1.27M
DDOG icon
88
Datadog
DDOG
$94B
$1.19M 0.03%
9,600
+2,100
+28% +$264K
KRON
89
DELISTED
Kronos Bio
KRON
$1.1M 0.03%
842,954
– –
GOOGL icon
90
Alphabet (Google) Class A
GOOGL
$4.12T
$1.06M 0.03%
7,000
-800
-10% -$114K
MSFT icon
91
Microsoft
MSFT
$2.9T
$1.05M 0.03%
2,500
– –
SNOW icon
92
Snowflake
SNOW
$98.1B
$1.05M 0.03%
+6,500
New +$1.26M
INTA icon
93
Intapp
INTA
$2.44B
$1.01M 0.03%
29,500
+12,000
+69% +$471K
IRWD icon
94
Ironwood Pharmaceuticals
IRWD
$586M
$963K 0.02%
110,532
– –
ACHL
95
DELISTED
Achilles Therapeutics
ACHL
$944K 0.02%
755,375
-1,500,000
-67% -$1.62M
PANW icon
96
Palo Alto Networks
PANW
$256B
$852K 0.02%
+6,000
New +$946K
AMD icon
97
Advanced Micro Devices
AMD
$700B
$812K 0.02%
4,500
+2,000
+80% +$350K
PCOR icon
98
Procore
PCOR
$7.57B
$781K 0.02%
9,500
– –
PEGA icon
99
Pegasystems
PEGA
$5.09B
$743K 0.02%
23,000
– –
MDB icon
100
MongoDB
MDB
$25.8B
$717K 0.02%
2,000
+1,000
+100% +$409K
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group withdrew a net $123M in Q1 2024, closing 20 positions and reducing 17 holdings. Its most notable exit was argenx, an estimated $44.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Crinetics Pharmaceuticals worth $65.1M.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.